TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE

• US 20140234397A1
• Filed: 03/15/2013
• Published: 08/21/2014
• Est. Priority Date: 02/15/2013
• Status: Abandoned Application

• Current Assignee: Frederick Timothy Guilford, Lou Ann Brown
• Original Assignee: Frederick Timothy Guilford, Lou Ann Brown
• Inventors: Guilford, Frederick Timothy, Brown, Lou Ann
• Application Number:
  US13/832,229
• Publication Number:
  US 20140234397A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 38/063 Glutathione
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.

Claims

1. The use of a composition of liposomally formulated glutathione for treatment of a mammalian patient having Klebsiella Pneumoniae.

2. A method of treatment of a mammalian patient having Klebsiella Pneumoniae comprising:

administering liposomally formulated glutathione